Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials
Executive Summary
While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop
You may also be interested in...
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics
FDA would like to slow the escalating momentum behind adaptive clinical trial designs to allow time to craft better working definitions of the new models and build a better base before moving forward, agency officials indicated at a Pharmaceutical Research & Manufacturers of America workshop